Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Biofrontera Inc (BFRI)

Biofrontera Inc (BFRI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,344
  • Shares Outstanding, K 5,089
  • Annual Sales, $ 34,070 K
  • Annual Income, $ -20,130 K
  • 60-Month Beta 0.65
  • Price/Sales 0.16
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade BFRI with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -1.19
  • Number of Estimates 1
  • High Estimate -1.19
  • Low Estimate -1.19
  • Prior Year -6.14
  • Growth Rate Est. (year over year) +80.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0002 +4.98%
on 05/24/24
2.1300 -50.70%
on 05/02/24
-0.6100 (-36.75%)
since 04/24/24
3-Month
0.7605 +38.07%
on 02/29/24
2.4302 -56.79%
on 04/10/24
+0.1300 (+14.13%)
since 02/23/24
52-Week
0.6100 +72.13%
on 02/08/24
13.4200 -92.18%
on 06/20/23
-8.9400 (-89.49%)
since 05/24/23

Most Recent Stories

More News
Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Tops Revenue Estimates

Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 2.21% and 67.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

BEAM : 24.32 (+1.29%)
BFRI : 1.0500 (-0.94%)
Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates

Editas (EDIT) delivered earnings and revenue surprises of 10.13% and 97.42%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

EDIT : 5.63 (-3.43%)
BFRI : 1.0500 (-0.94%)
Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Misses Revenue Estimates

Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -1.45% and 30.28%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

KYMR : 34.05 (-0.55%)
BFRI : 1.0500 (-0.94%)
Biofrontera Inc. (BFRI) Reports Q3 Loss, Tops Revenue Estimates

Biofrontera Inc. (BFRI) delivered earnings and revenue surprises of 28.13% and 0.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

BFRI : 1.0500 (-0.94%)
VBLT : 5.4600 (-8.77%)
Entera Bio Ltd. (ENTX) Reports Q3 Loss, Misses Revenue Estimates

Entera Bio Ltd. (ENTX) delivered earnings and revenue surprises of 31.25% and 88.57%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ENTX : 2.32 (+0.43%)
BFRI : 1.0500 (-0.94%)
Curis (CRIS) Reports Q3 Loss, Misses Revenue Estimates

Curis (CRIS) delivered earnings and revenue surprises of 17.65% and 6.77%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

CRIS : 11.20 (+0.54%)
BFRI : 1.0500 (-0.94%)
Global Laser Therapy Devices Billion Dollar Market Thriving on Growing Demand

Palm Beach, FL – October 4, 2022 – FinancialNewsMedia.com News Commentary –  The laser therapy market has been having a very health growth trend in recent years and is expected to continue through...

PIXY : 1.7550 (+5.97%)
EW : 87.98 (+0.59%)
BFRI : 1.0500 (-0.94%)
LITE : 46.28 (+0.78%)
CUTR : 2.06 (unch)
Global Laser Therapy Devices Billion Dollar Market Thriving on Growing Demand

/PRNewswire/ -- The laser therapy market has been having a very health growth trend in recent years and is expected to continue through the coming years....

PIXY : 1.7550 (+5.97%)
EW : 87.98 (+0.59%)
BFRI : 1.0500 (-0.94%)
LITE : 46.28 (+0.78%)
CUTR : 2.06 (unch)
Biofrontera Inc. Announces Patent in Australia for Novel Illumination Protocols Granted to Biofrontera Bioscience GmbH

Patent Improves Differentiated Profile of Ameluz-PDT by Expected Reduced Pain Intensity while Maintaining Efficacy WOBURN, Mass., Aug. 01, 2022 (GLOBE...

BFRI : 1.0500 (-0.94%)
BFRIW : 0.0525 (+30.60%)
Biofrontera Inc. Announces Exercise of Existing Warrants and Issuance of Warrants in Private Placement

WOBURN, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of...

BFRIW : 0.0525 (+30.60%)
BFRI : 1.0500 (-0.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Biofrontera Inc. is a biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on the fields of photodynamic therapy and topical antibiotics. The Company's licensed products focus on the treatment of actinic keratoses,...

See More

Key Turning Points

3rd Resistance Point 1.1497
2nd Resistance Point 1.1099
1st Resistance Point 1.0799
Last Price 1.0500
1st Support Level 1.0101
2nd Support Level 0.9703
3rd Support Level 0.9403

See More

52-Week High 13.4200
Fibonacci 61.8% 8.5266
Fibonacci 50% 7.0150
Fibonacci 38.2% 5.5034
Last Price 1.0500
52-Week Low 0.6100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar